Publication:
Oral human β-defensin 2 in HIV-infected subjects with long-term use of antiretroviral therapy

0
0

Issued Date

2013

Resource Type

Article

File Type

application/pdf

ISSN

9042512

DOI

10.1111/j.1600-0714.2012.01183.x

Other identifier(s)

2-s2.0-84871937661

Rights Holder(s)

มหาวิทยาลัยศรีนครินทรวิโรฒ

Bibliographic Citation

Journal of Oral Pathology and Medicine. Vol 42, No.1 (2013), p.53-60

Suggested Citation

Nittayananta W., Kemapunmanus M., Amornthatree K., Talungchit S., Sriplung H. Oral human β-defensin 2 in HIV-infected subjects with long-term use of antiretroviral therapy. Journal of Oral Pathology and Medicine. Vol 42, No.1 (2013), p.53-60. doi:10.1111/j.1600-0714.2012.01183.x Retrieved from: https://hdl.handle.net/20.500.14740/6837

Title

Oral human β-defensin 2 in HIV-infected subjects with long-term use of antiretroviral therapy

Author(s)

Nittayananta W.
 Kemapunmanus M.
 Amornthatree K.
 Talungchit S.
 Sriplung H.

Abstract

Background: The objectives of this study were to determine (i) oral hBD2 expression in HIV-infected subjects compared with non-HIV controls, (ii) the expression of oral hBD2 in HIV-infected subjects with antiretroviral therapy (ART) compared with those without ART, and (iii) factors associated with the expression of oral hBD2. Methods: Oral examination and punched biopsy on buccal mucosa were performed in HIV-infected subjects with and without ART, and non-HIV individuals. The expression of hBD2 mRNA was determined by quantitative real-time PCR. Saliva samples of both un-stimulated and stimulated saliva were collected and analyzed for hBD2 levels using ELISA. Student's t-test and nonparametric multi-way ANOVA test were used for comparison of measurements between or among groups. Results: One hundred and fifty-seven HIV-infected subjects were enrolled: 99 on ART (age range, 23-57years; mean 39years), 58 not on ART (age range, 20-59years; mean 34years), and 50 non-HIV controls (age range, 19-59years; mean 36years). The most common ART regimen was two nucleoside reverse transcriptase inhibitors+one non-nucleoside reverse transcriptase inhibitor. Salivary levels of hBD2 were significantly increased in HIV infection (P<0.001). The levels of hBD2 in stimulated saliva were also found to be significantly different between HIV-infected subjects who were and were not on ART (P<0.001). No significant difference was observed with the expression of hBD2 mRNA. Conclusion: Oral innate immunity is affected by HIV infection and use of ART. Salivary hBD2 levels may be the useful biomarkers to monitor those on long-term ART who are at risk of developing oral infections and malignant transformation. © 2012 John Wiley & Sons A/S.

Subject(s)

Beta defensin 2
 RNA directed DNA polymerase inhibitor
 Adult
 Article
 Cheek mucosa
 Controlled study
 Cross-sectional study
 Enzyme linked immunosorbent assay
 Female
 Highly active antiretroviral therapy
 Human
 Human immunodeficiency virus infected patient
 Human immunodeficiency virus infection
 Human tissue
 Major clinical study
 Male
 Measurement
 Mouth examination
 Priority journal
 Protein expression
 Real time polymerase chain reaction
 Saliva analysis
 Adult
 Analysis of Variance
 Anti-HIV Agents
 Antimicrobial Cationic Peptides
 Beta-Defensins
 Case-Control Studies
 CD4 Lymphocyte Count
 Cross-Sectional Studies
 Female
 HIV Infections
 Humans
 Immunity, Innate
 Male
 Middle Aged
 Mouth Mucosa
 Regression Analysis
 Reverse Transcriptase Inhibitors
 Reverse Transcriptase Polymerase Chain Reaction
 Salivary Proteins and Peptides
 Statistics, Nonparametric
 Viral Load
 Young Adult

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/6837

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By